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Summary
The Cancer Genome Atlas (TCGA) has given researchers
and clinicians unprecedented access to many different can-
cers through multiple platforms that include exome sequen-
cing, comparative genomic hybridisation (CGH) arrays,
DNA methylation arrays, RNA sequencing, reverse protein
phase arrays (RPPA), and clinical features. Most data are
available to the public in their raw and processed forms;
however, analysis and interpretation of these data require
specialised training and software. To address this problem,
online tools such as cBioportal, canEvolve, GDAC fire-
hose, PROGgeneV2, and UCSC Cancer browser have been
developed by various groups to explore and perform ana-
lyses on the datasets that are easily understandable by basic
researchers and clinicians. In this mini-review, we give an
overview of the datasets available from TCGA and the pub-
lic tools available for integrative analysis of survival with
the genomic and transcriptomic datasets, and introduce a
tool being developed by our group to analyse the datasets
within TCGA.
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Introduction
The Cancer Genome Atlas (TCGA) [1] has generated gen-
omic, transcriptomic, epigenomic and clinical data for sev-
eral cancer types, which are publically available for every
clinician and researcher to explore and analyse. To date,
there are 10 000 cases of 33 tumour types available, with
20 cancer types having more than 200 cases (table 1). The
data are centralised at the TCGA data portal and can be
downloaded for academic use. Many groups have used
TCGA data to characterise the genomic and molecular
landscape of multiple cancer types, and have used the data
to perform novel analysis. For instance, integrative analysis
of exome sequencing, RNAseq and miRNAseq across
12 cancer types revealed 11 major subtypes and redefined
three cancer types into one molecular subgroup [2]. Anoth-
er group used the exome sequencing and RNAseq data for
six cancer types and discovered that neoantigen expression
could predict patient survival [3].
The data types listed on the TCGA data portal for each
cancer are somatic mutation, copy number, gene expres-
sion, miRNA expression, DNA methylation, reverse pro-
tein phase array (RPPA) and clinical information. Each data
type has the raw and processed data available for public
download, except for the raw sequencing files from the ex-
ome sequencing, RNA sequencing (RNAseq), microRNA
sequencing (miRNAseq) and copy number, which require
authorisation from the Cancer Genomics Hub (CGHub).
The analysis pipelines for each data type are available in
a text file included with the data. By providing a standard
method for raw data processing and annotation, it allows
reproducibility in downstream analysis by other research
groups.
Data types within TCGA
Here we briefly describe each data type, the method used
to obtain the data and the information it provides.
Somatic mutations are determined by use of exome sequen-
cing. Exome sequencing detects single nucleotide variants,
which are categorised as nonsynonymous or synonymous.
Nonsynonymous single nucleotide variants cause single
amino-acid substitutions, which may lead to altered protein
function or truncated proteins.
Copy number alterations are determined with the Affymet-
rix SNP6.0 array. This array detects gains and losses of the
genome, typically at a resolution of 100‒200 kilobases.
Gene expression and microRNA expression are determined
with RNAseq and miRNAseq, respectively. The abundance
of transcripts, isoforms, novel transcripts, gene fusions, and
noncoding RNAs can be extracted from the sequencing
data.
DNA methylation is determined with the Infinium Human
Methylation 450 Bead Array. This array provides single
nucleotide resolution of CpGs across the vast majority of
CpG islands and promoters of the genome.
Protein expression is determined with RPPA. RPPA is an
array-based method of detecting proteins at nanogram
levels. Validated antibodies are used to assess protein level
as well as phosphor-protein levels. This allows for detec-
tion of activated proteins which could not be inferred from
RNA expression.
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Clinical data is listed for each patient with standard metrics
such as age, gender, time to death or last known contact
date. For each cancer there are specific stratification para-
meters, for instance Gleeson score for prostate cancer and
Breslow index for melanoma. Overall survival as well as
progression-free survival can be calculated and stratified
according to cancer-specific staging.
Overall, each data type is very comprehensive in covering
the genome, and current analysis techniques usually correl-
ate each data type separately with the clinical survival data.
In the future, integrative analysis in a multi-omics fashion
would be ideal in order to understand the biology of the
cancer and its effect on patient survival.
Public webtools for analysing TCGA
data
With the large amount of data available, specialised web-
based tools have been developed to aid clinicians and re-
Figure 1
Snapshot of UZH Cancer Browser. Left panel shows selectable
parameters for gene, patient percentile, survival time and tumor
type. Normalised expression of NGFR accross all patients can be
seen in the scatterplot in the bootom left corner. In the main panel
of the webtool, tabs for the analysis modules can be selected for
visualisation. In this snapshot the survival curve module is selected
and the Kaplan-Meier plot is shown.
searchers to analyse and interpret all the data types in a
meaningful way. Websites such as cBioportal [5], GDAC
firehose (http://gdac.broadinstitute.org), canEvolve [6],
PROGgeneV2 [7], and the UCSC cancer browser [8] all
provide their own analysis and visualisation tools for
TCGA datasets (table 2).
The cBioportal website hosts over 20 000 tumour samples
from 89 cancer studies, which include all the TCGA data.
The website allows the user to select a dataset and enter a
list of genes or a pre-generated gene list. The cBioportal
offers unique analyses like OncoPrint diagrams, MEMo
(Mutual Exclusivity Modules) analysis, customisable cor-
relation plots, Kaplan-Meier plots, network analysis and in-
tegrative genomics viewer integration. Oncoprint diagrams
are a simple way to present genomic alterations like so-
matic mutations and copy number alterations across a set
of samples. These diagrams allow the user to detect visu-
ally co-occurrence or mutual exclusivity of genomic altern-
ations within a cohort. MEMo analysis identifies mutations
in genes sharing a pathway and exhibiting a pattern of mu-
tually exclusive mutations across a cohort [9]. The cBi-
oportal provides analysis of the RNAseq and RPPA data
types by setting z-score thresholds for significant genes and
proteins, respectively. Network analysis integration with
Cytoscape allows the user to view gene networks and their
interactions for selected genes. Integrative genomics view-
er integration allows for users to visualise easily copy num-
ber alterations, mutations and gene expression across all
the chromosomes at a genome level. Finally, all data ana-
lysed can be downloaded in table format for further analys-
is.
GDAC firehose preprocesses annotated data from TCGA
and provides correlations and differential gene analysis
across all data types. GDAC firehose periodically updates
with new TCGA cases and performs automated pipelines
on all the data every 4 months. Unique analysis pipelines
from GDAC firehose include GISTIC2 analysis of copy
number data [10], MutSig2 analysis of mutation data [11],
and PARADIGM analysis of copy number and RNAseq
Table 1: Cancer types with data available via The Cancer Genome Atlas.
Cases
Acute myeloid leukaemia (LAML) 200
Bladder urothelial carcinoma (BLCA) 412
Brain lower grade glioma (LGG) 516
Breast invasive carcinoma (BRCA) 1 098
Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) 308
Colon adenocarcinoma (COAD) 461
Glioblastoma multiforme (GBM) 528
Head and neck squamous cell carcinoma (HNSC) 528
Kidney renal clear cell carcinoma (KIRC) 536
Kidney renal papillary cell carcinoma (KIRP) 291
Liver hepatocellular carcinoma (LIHC) 377
Lung adenocarcinoma (LUAD) 521
Lung squamous cell carcinoma (LUSC) 504
Ovarian serous cystadenocarcinoma (OV) 586
Prostate adenocarcinoma (PRAD) 498
Sarcoma (SARC) 261
Skin cutaneous melanoma (SKCM) 470
Stomach adenocarcinoma (STAD) 443
Thyroid carcinoma (THCA) 507
Uterine corpus endometrial carcinoma (UCEC) 548
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data [12]. GDAC firehose also provides correlation of the
clinical data with miRNA, mRNA, RPPA, copy number
and DNA methylation datasets. They also perform cluster-
ing analysis for each data type and define molecular sub-
types, which are then correlated to the clinical, mutation
and copy number data.
The canEvolve site hosts over 10 000 tumour samples from
90 cancer studies, which include 15 TCGA datasets. This
web portal allows the user to select a database and perform
multiple downstream analyses, which include differential
gene expression, miRNA expression, copy number analys-
is, regulatory network analysis using ARACNE [13], co-
expression network analysis using WGCNA [14], gene set
enrichment analysis using the MSigDB 3.0 gene sets [15],
integrative gene expression and miRNA expression ana-
lysis using GemiNI [16], integrative gene expression and
copy number analysis using DR-Integrator [17], integrat-
ive genomic and gene expression analysis, integrative gen-
omic and protein expression analysis and survival analysis.
In addition, canEvolve allows gene queries across multiple
datasets, where the user can select a pre-defined gene list
from KEGG or Biocarta pathway or supply their own gene
list and interrogate the pattern of gene expression in a giv-
en dataset.
PROGgeneV2 is the second iteration of PROGgene. It is a
web tool that contains over 19 000 samples from 134 co-
horts in 21 cancer types. PROGgeneV2 mainly provides
survival analyses based on expression of one gene or the
ratio between two genes, which is unique to this tool. Sur-
vival plots can also be created using gene signatures from
GO, KEGG, Biocarta and Reactome databases, and from
published studies. Covariate data, such as stage of the can-
cer, can also be adjusted for the survival plots. Another
unique feature for PROGgeneV2 is the option for users to
upload their own data to the website. As omics datasets be-
come more widely applied by end-users with less informat-
ics training, this feature will become increasingly more im-
portant in order to understand how individual patient data
compares with much larger cohorts.
The UCSC cancer browser also provides visualisation and
analysis tools for the TCGA datasets. Unique to this tool is
the interactive analysis of multiple datatypes for a cancer
dataset. The user can select a dataset to visualise from a
menu, such as gene expression or DNA methylation, and
then stratify according to clinical parameters or another
dataset. For instance, the user can select for the mutated
genes dataset in a cancer and stratify according to the clus-
tering of miRNA and DNA methylation signatures. This al-
lows the user to define specific subgroups within the can-
cer and subsequently to perform survival analyses on these
subgroups. The user can also specify which genes or gene
signatures to visualise within a dataset. Users can upload
their own annotations to the clinical heatmap for specif-
ic clustering. The UCSC cancer browser will be updated
in the future, with the new Xena platform for visualisation
and integration with Galaxy [18, 19].
UZH webtool for TCGA analysis
Our laboratory is also developing a tool for visualising and
analysing the TCGA data with a focus on survival ana-
lyses based on expression-based patient stratification: (ht-
tp://www.cancer.uzh.ch/research/Three/webtool.html/). As
this tool is still in development, features are still be updated
and new features will be added. Here, we briefly describe
the current build of the tool (June 2015). To use the
webtool, the user enters a gene in the textbox in the left
sidebar and can observe the distribution of expression of
that gene across the entire cancer class in the dot plot in
the lower portion of the left sidebar. The user can select
the percentile of patients to compare in the slider below
the textbox and select which tumour entities are included
in the analysis by checking the boxes below the slider. In
the main panel of the web tool there are tabs for survival,
univariate and multivariate Cox regression, mutation pro-
file, copy number profile, combined mutation and copy
number profile, differential gene expression presented as a
heat map and table of genes, bar graphs comparing clin-
ical features with gene expression, differential protein ex-
pression presented as a heat map and table, and, finally,
pathway analysis by KEGG pathway and StringDB. For
example, the transcript of the NGFR gene, which encodes
the CD271 protein that has been associated with melanoma
progression [20, 21], has an exponential distribution with a
very long tail, resembling a power-law distribution (fig. 1).
Thus, comparison of the top and bottom patient quartiles is
more meaningful for subsequent analyses than when just a
standard 50% threshold is used, because the other 50% of
the patients do not provide additional information and di-
lute the effect of the high-NGFR expressing tumours.
Overall, this web tool attempts to combine visualisation
and differential gene analyses for the user to interpret the
TCGA data based on single gene selection.
Table 2: Webtools for TCGA analysis.
Webtool Kaplan Meier
plots
Mutation
analysis
Correlation
analysis
Differential
expression
analysis
Pathway
analysis
Pan-cancer
analysis
Number of
samples
URL
cBioportal x x x x x >20 000 http://www.cbioportal.org/
GDAC firehose x x x >10 000 http://gdac.broadinstitute.org/
canEvolve x x x x x x >10 000 http://www.canevolve.org
PROgeneV2 x >19 000 http://watson.compbio.iupui.edu/
chirayu/proggene/database/
?url=proggene
UCSC Cancer browser x x x >10 000 https://genome.ucsc.edu/
UZH Cancer Browser x x x x >1 000 http://www.cancer.uzh.ch/
research/Three/webtool.html
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Conclusions
All these web tools provide their specific methods of ana-
lysis and each has its advantages for visualisation and in-
terpretation of the TCGA data. Since all these tools used
the processed data generated from the TCGA, all analyses
should be reproducible by using the same analysis
pipelines. The cBioportal and UCSC cancer browser focus
on visualisation of the TCGA data with some support for
survival and correlation analysis. GDAC firehose and can-
Evolve focus on analysis of the TCGA data performing
many correlation analysis and integrative analysis of the
data types within one cancer. PROGgeneV2 is a survival
analysis centric tool only focusing on gene expression and
survival. Our web tool focuses on gene expression and sur-
vival and performs subsequent analyses on mutation and
copy profile, differential gene and protein expression and
pathway analysis.
In summary, the TCGA is an immensely powerful resource
for cancer genome data mining. Many tools have been de-
veloped to allow basic researchers and clinicians without
bioinformatics training to visualise, analyse and interpret
the data. But concerted efforts between bioinformaticians,
biologists and clinicians are still needed to understand fully
this vast amount of data and to translate it into testable hy-
potheses and novel diagnostic and therapeutic options for
the clinic.
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Figures (large format)
Figure 1
Snapshot of UZH Cancer Browser. Left panel shows selectable parameters for gene, patient percentile, survival time and tumor type.
Normalised expression of NGFR accross all patients can be seen in the scatterplot in the bootom left corner. In the main panel of the webtool,
tabs for the analysis modules can be selected for visualisation. In this snapshot the survival curve module is selected and the Kaplan-Meier plot
is shown.
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